U.S. Food and Drug Administration Grants Second Approval for Epkinly® (Epcoritamab-Bysp) to Treat Patients With Relapsed or Refractory Follicular Lymphoma
美國食品藥品監督管理局授予 Epkinly® (Epcoritamab-Bysp)第二次批准,用於治療復發或難治性濾泡性淋巴瘤患者。
U.S. Food and Drug Administration Grants Second Approval for Epkinly® (Epcoritamab-Bysp) to Treat Patients With Relapsed or Refractory Follicular Lymphoma
美國食品藥品監督管理局授予 Epkinly® (Epcoritamab-Bysp)第二次批准,用於治療復發或難治性濾泡性淋巴瘤患者。
譯文內容由第三人軟體翻譯。